Pro-Pharmaceuticals is a development-stage company engaged in the discovery, development, and commercialization of first-in-class, carbohydrate-based, targeted therapeutic compounds for advanced treatment of cancer, liver, microbial and inflammatory diseases. The Company’s initial focus is the development of a new generation of anti-cancer treatments using carbohydrate polymers to increase survival and improve the quality of life for cancer patients. The need to improve drug therapies, particularly anti-cancer agents, is significant and represents a large market opportunity. DAVANAT®, the Company’s lead pipeline candidate, is a proprietary new chemical entity that is currently in Phase II trials for first-line treatment of colorectal and biliary cancer.

The Company’s targeted therapeutic compounds can also be used to treat other serious diseases, such as liver and kidney fibrosis. To this extent, Pro-Pharmaceuticals has entered into research collaborations with the Mount Sinai School of Medicine in New York to study the anti-fibrotic effects of its carbohydrate compounds on liver fibrosis; with the Brigham and Women’s Hospital in Boston to evaluate the anti-fibrotic effects of these compounds at treating acute and chronic kidney disease; and with the University of California at Davis and Fudan University in Shanghai to conduct further anti-fibrosis tests. The Company’s novel compounds have shown to reduce collagen expression and reverse fibrosis in animal models. Whereas previous in vitro data has only indicated a reversal of fibrosis markers, in a recent proof-of-concept animal study, the compounds both significantly reduced collagen expression and reversed liver fibrosis.